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Background: People with end-stage kidney disease treated with dialysis experience high rates of premature death
that are at least 30-fold that of the general population, and have markedly impaired quality of life. Despite this,
interventions that lower risk factors for mortality (including antiplatelet agents, epoetins, lipid lowering, vitamin D
compounds, or dialysis dose) have not been shown to improve clinical outcomes for this population. Although
mortality outcomes may be improving overall, additional modifiable determinants of health in people treated with
dialysis need to be identified and evaluated.
Oral disease is highly prevalent in the general population and represents a potential and preventable cause of poor
health in dialysis patients. Oral disease may be increased in patients treated with dialysis due to their lower uptake
of public dental services, as well as increased malnutrition and inflammation, although available exploratory data
are limited by small sample sizes and few studies evaluating links between oral health and clinical outcomes for
this group, including mortality and cardiovascular disease. Recent data suggest periodontitis may be associated
with mortality in dialysis patients and well-designed, larger studies are now required.
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Methods/design: The ORAL Diseases in hemodialysis (ORAL-D) study is a multinational, prospective (minimum
follow-up 12 months) study. Participants comprise consecutive adults treated with long-term in-center
hemodialysis. Between July 2010 and February 2012, we recruited 4500 dialysis patients from randomly selected
outpatient dialysis clinics in Europe within a collaborative network of dialysis clinics administered by a dialysis
provider, Diaverum, in Europe (France, Hungary, Italy, Poland, Portugal, and Spain) and South America (Argentina).
At baseline, dental surgeons with training in periodontology systematically assessed the prevalence and
characteristics of oral disease (dental, periodontal, mucosal, and salivary) in all participants. Oral hygiene habits and
thirst were evaluated using self-administered questionnaires. Data for hospitalizations and mortality (total and
cause-specific) according to baseline oral health status will be collected once a year until 2022.
Discussion: This large study will estimate the prevalence, characteristics and correlations of oral disease and clinical
outcomes (mortality and hospitalization) in adults treated with dialysis. We will further evaluate any association
between periodontitis and risk of premature death in dialysis patients that has been suggested by existing research.
The results from this study should provide powerful new data to guide strategies for future interventional studies
for preventative and curative oral disease strategies in adults who have end-stage kidney disease.
Keywords: Chronic kidney disease, Oral disease, Periodontitis, Mortality, PrevalenceBackground
The prevalence of chronic kidney disease (clinically-rele-
vant structural kidney changes or urinary abnormalities,
with or without reduced estimated glomerular filtration
rate [below 60 ml/min per 1.73 m2]) [1] is increasing
globally, due in part to international epidemics of obesity
and diabetes mellitus. Approximately 10% to 15% of the
global adult population is affected by chronic kidney
disease [2-4]. In addition to an increasing prevalence,
chronic kidney disease is associated with markedly
impaired quality of life, sexual dysfunction, unemploy-
ment, depression, and premature mortality [5,6]. Moder-
ate kidney disease (estimated glomerular filtration rate
below 44 ml/min per 1.73 m2 and/or heavy proteinuria)
is associated with a 2- to 3- fold increase in all-cause
mortality compared with the general population and for
dialysis patients the risk is much higher [7,8]. Despite
poorer clinical outcomes, pharmacologic and dialysis-
related interventions (including anti-platelet agents, [9]
dialysis dose, [10] early dialysis initiation, [11] vitamin D
compounds, [12] erythropoietins [13], phosphodiesterase-5
inhibitors, [14] or antidepressant medication [15-20])
generally do not improve clinical outcomes or quality of
life, particularly for those with end-stage kidney disease
treated with dialysis. Exploration of additional and modifi-
able determinants of health in populations with chronic
kidney disease would help prioritize the evaluation of novel
intervention strategies to improve clinical outcomes.
Oral disease represents a potential and preventable
cause of impaired health in people with chronic kidney
disease. Oral disease, including dental decay and peri-
odontitis, affects nearly all adults in the global popula-
tion [21] and is amongst one of the most costly diseases
to treat for many health systems [21,22]. Chronic diseaseis particularly linked to poorer oral health and greater
unmet dental need, including untreated dental disease,
self-reported poor oral health, and tooth loss [23]. In
addition, individuals who have chronic kidney disease
(estimated glomerular filtration rate below 60 ml/min
per 1.73 m2) are much less likely than the general popu-
lation to attend publicly available dental care, even when
controlling for age, gender, race or ethnicity, language
barriers, medical insurance and income [24]. Periodontal
disease is associated with cardiovascular disease in the
general population [25] and emerging data suggest a link
between periodontitis and mortality in people with
chronic kidney disease treated with dialysis [26,27]. Oral
disease is associated with inflammation [28] and malnu-
trition (including the protein-energy wasting syndrome)
[29,30], which affect people who have chronic kidney
disease disproportionately, and are considered linked
risk factors for accelerated cardiovascular disease in this
clinical setting (known as malnutrition, inflammation,
and atherosclerosis [MIA] syndrome) [31]. The relative
contributions of socioeconomic disadvantage, malnutri-
tion and inflammation to the prevalence and outcomes
of oral disease in people who have kidney disease require
analysis in a large longitudinal study, ahead of potential
interventional trials.
Existing data for the prevalence and severity of oral
disease in chronic kidney disease patients are confined
to a few studies that have small sample sizes and marked
differences in the estimates of oral disease between stud-
ies that are not readily explained by study-level clinical
or demographic characteristics [32]. The ORAL Diseases
in hemodialysis (ORAL-D) study has been designed to
survey the prevalence, severity, correlates, and outcomes
of oral disease in a large consecutive population of
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hemodialysis to assist the prioritization of future inter-
ventional research for oral disease in this population.
Robust data linking oral health to relevant clinical
outcomes may additionally identify the need for specific
interventional trials in dialysis patients.
The ORAL-D study was specifically designed to explore
the following questions:
1. Is the prevalence of oral disease higher in adults
treated with hemodialysis and does the pattern of
oral disease indicate/correlate with lower use of
preventative dental services?
2. What are the important correlates of oral disease in
hemodialysis patients including sociodemographic
and clinical factors?
3. What is the prevalence of thirst and dysgeusia
symptoms in adults treated with hemodialysis?
4. What are the characteristics and correlates of
preventative oral habits including teeth brushing,
attendance at dental care, flossing, and use of
mouth wash?
5. Is there a relationship between biochemical and
clinical performance measures used to evaluate
quality of dialysis care and the prevalence and
severity of oral disease?
6. What is the association between oral disease (dental,
periodontal, salivary, or mucosal) and hospitalization
or premature mortality in hemodialysis patients?
Hypothesis
In the largest cohort study of oral disease in dialysis
patients to date (the ORAL Diseases in Hemodialysis
[ORAL-D] study), we will test the hypothesis that oral
disease is frequently experienced by patients with end-
stage kidney disease treated with hemodialysis and
increases risk of total and cause-specific hospitalization and
mortality when controlling for potentially confounding
factors. We have evaluated oral hygiene habits and thirst in
this population and whether biochemical and clinical
performance measures of dialysis care are associated with
increased risks of all forms of oral disease.
Methods/design
We received ethics approval for the ORAL Diseases
in Hemodialysis (ORAL-D) study from the following
responsible local Human Research Ethics Committees:
Comitè de Protection des Personnes Sud-Medierranèe II
(France), Komisja Bioetyczna, Slaskiego Uniwersytetu
Medycznego W Katowicach (Poland), CE da Diaverum
Portugal (Portugal), Comite Etico de Investigacion Clinica
(CEIC) de la Fundaction Puygvert and Agencia Valenciana
de Salud, Departament de Salut Valencia (Spain), and
Szegedi Tudomanyegyetem, Szent-Gyorgyi albert klinikaikozpont, and Regionalis human orvosbiologiai kutatasetikai
bizottsaga (Hungary). Ethics approval was not required for
this type of study in Italy or Argentina. All participants pro-
vided written and informed consent prior to study initiation
and patient enrolment. The study is being performed in ac-
cordance with the 2000 Edinburgh, Scotland Revision of
the Declaration of Helsinki, applicable ICH guidelines and
Guidelines on Research Practice.
Study design
This is a multinational, prospective (minimum 12
months’ follow-up) study, in which approximately 4500
patients with end-stage kidney disease treated with out-
patient in-center hemodialysis within a collaborative
network of dialysis clinics administered by a dialysis
provider (Diaverum) were enrolled between July 2010
and February 2012. The clinics included in this study
were from dialysis communities with heterogeneity in
social and economic circumstances and for which local
investigators had committed to providing good-quality
data during study follow-up.
Patient population
The study is multinational and open to all outpatient
Diaverum haemodialysis treatment centers in selected
countries in Europe (France, Hungary, Italy, Poland,
Portugal, and Spain) and South America (Argentina).
Eligible patients have met the following inclusion
criteria:
1. End-stage kidney disease
2. Currently on long-term hemodialysis for any
duration
3. Aged 18 years or over
4. Treating team agreeable to patient’s involvement in
the study
5. Able to provide written and informed consent
Study procedures
Patients had met the inclusion criteria and all provided
informed consent. Processes to identify and screen all
potential recruits were established within each center in
consultation with the ORAL-D study Steering Commit-
tee. Patient consent forms were approved by the Human
Research Ethics Committee before the beginning the
study. A sample consent form and patient information
sheet was provided to participating sites. Participating
sites filed a copy of the approved consent form and in-
formation sheet for their center with the coordinating
study office. The patient had an initial consultation with
study personnel to discuss study participation, which in-
cluded a preliminary eligibility check. The patient was
also given an information sheet for the study. If consent
was provided by the patient, a copy of the signed
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participant. The participant gave written and informed
consent before enrollment or completion of any
study-specific procedures. The ORAL-D study Steering
Committee monitored the medical literature and any
other relevant information that might have impacted on
the ongoing conduct of the study.
The study commenced on the day of enrollment. At
enrollment, all participants underwent: 1) collection of
demographic and clinical data including dialysis-related
care; 2) completion of self-administered questionnaires
on oral hygiene and thirst; and 3) comprehensive and
systematic oral examination, including assessment of
dental, periodontal, mucosal, and salivary characteristics
(including pH and flow).
Demographic and clinical data
The collection of demographic, clinical/laboratory and
dialysis-related data were performed by the local treating
physician on standardized case report forms within one
month of enrollment. Relevant data were obtained from
clinical databases linked to the patient via a standardized
identification code. Standardized data variables includedFigure 1 Self-administered questionnaire on oral habits.age, gender, race, country of residence, educational,
marital and occupational status, alcohol intake, smoking
history, physical activity, housing, distance from dialysis
unit, menopausal status, body mass index, protein cata-
bolic rate, family income, financial stress, food intake,
cause of kidney disease, diabetic status and other comor-
bid conditions, medication prescription, and serum pa-
rameters including hemoglobin, phosphorus, parathyroid
hormone, calcium, ferritin, albumin, cholesterol, and
dialysis parameters. We included specific collection of
data for medications to treat depression and anxiety that
may have dry mouth as a side-effect as well as oral anti-
coagulants to evaluate their association with oral
bleeding.
Self-administered questionnaires
At baseline, all participants completed self-administered
questionnaires to evaluate oral hygiene habits, [33] and
thirst [34]. Oral hygiene habit data included questions
about visits for dental care, brushing, mouth wash use,
and dental floss practices, and duration of oral hygiene
each day (Figure 1). The dialysis thirst inventory was
used to ask patients about thirst as a clinical symptom
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thirst in relation to dialysis (Figure 2).
Oral examination
All patients were examined at baseline by a qualified
dental surgeon with training in periodontology in each
country who had been centrally trained on the protocol
and methods used for the study. The standardized oral
examination included analysis of dental, periodontal,
mucosal and salivary health. The oral examination
occurred in the dialysis unit on the day of dialysis. We
performed the dental and periodontal examination
before dialysis treatment started (to minimize excessive
bleeding due to heparin administration). We collected
saliva before and after dialysis therapy and participants
completed all questionnaires during dialysis. We performed
oral visits in a specifically set up room at the dialysis clinical
with an appropriate chair and mobile light source, or in the
dialysis room using a light-emitting diode (LED) headlamp,
based on patient preference. We used a standard sterile oral
examination kit containing a dental examination mirror,
ball-tip periodontal probe (calibrated in millimeters),Figure 2 Self-administered dialysis thirst inventory questionnaire.tweezers, masks, bib, tissue wipes, cotton rolls and a bio-
degradable tray.
1. Dental examination
The DMFT index quantifies dental caries, fillings,
and tooth loss. In this study, the DMFT index was
calculated centrally for 32 teeth in the adult
dentition including the four wisdom teeth or third
molars. The dentist also recorded the total number
of teeth (maximum 32) and the presence or absence
of enamel hypoplasia and dental attrition or erosion.
If dental attrition or erosion was present, the dentist
indicated the likely cause. The dentist also recorded
the presence of any denture (partial or total).
2. Periodontal examination
The standardized periodontal examination included
the Periodontal Probing Depth (PPD), the Clinical
Attachment Loss (CAL) score and the Bleeding on
Probing (BOP) indices (Figure 3).
The Periodontal Probing Depth (PPD) was the
distance between the free gingival margin and the
apical extent of the periodontal pocket. The tip of
Figure 3 Standardized periodontal evaluation at baseline.
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(10 to 20 grams) into the gingival sulcus, which is an
area of potential space between a tooth and the
surrounding tissue. The first marking visible above
the pocket indicated the measurement of the pocket
depth. Three PPD measurements for each of the
vestibular and lingual aspects of the tooth were
recorded. A healthy pocket depth is approximately 3
mm without bleeding on probing. Depths greater
than 3 mm are associated with “attachment loss” of
the tooth to the surrounding alveolar bone,
characteristic of periodontitis. The PPD score was
calculated as a mean value expressed in millimeters
and determined as the total PPD divided by the
number of sites examined.
The same periodontal probe was used to measure
the distance between the cementum-enamel
junction (CEJ) and the free gingival margin (GM).
Clinical Attachment Loss (CAL) was calculated as
the sum of these distances, according to the
standard formula CAL = PPD + (GM – CEJ). The
CAL score for each patient was calculated as the
sum of the mean PPD (sum of all values divided by
the number of sites examined (6 per tooth)) and the
mean (GM-CEJ) (sum of all values divided by the
number of sites examined (2 per tooth)).
The Bleeding On Probing (BOP) index evaluated the
buccal, lingual, mesial and distal sulci of all teeth
recommended by the World Health Organization
based on the tendency to bleed after a standard
stimulus and indicating periodontal inflammation.
The four surfaces of each tooth were tested to
provide a maximum total of 128 sites. A final index
was obtained centrally and expressed as a percentage
of sites positive for bleeding on probing. The BOP
index was performed before the patient had received
heparin administration for dialysis treatment.
3. Mucosal examination
The dental surgeon asked the participant about
symptoms of oral pain, burning and dysgeusia
(altered sense of taste). For pain and burning
symptoms the patient indicated the severity of
symptoms on a Visual Analog Scale reporting a
value from 1 to 10. The dental surgeon also
evaluated the presence of ulceration, white or red
mucosal lesions, neoformation, petechial-ecchymosis,
thrush, herpes, geographical tongue, scrotal tongue,
uremic breath, previous surgery, and other lesions,
indicating the oral location, when present. Drug-
related gingival overgrowth (hypertrophy) was
assessed as present or absent.
4. Salivary indices
The participant was then asked not to eat, drink, or
smoke for an hour before the salivary analyses wereperformed. To estimate the salivary flow rate, the
patient chewed on a standard weight (1 gram) of
paraffin wax for 60 seconds and swallow the formed
saliva. Then, while chewing the paraffin intensively,
the saliva was spat into plastic sterile calibrated
containers (5 centimeters in diameter and provided
with a plastic cap) during the following 5 minutes.
The stimulated salivary flow rate was expressed in
milliliters per minute and measured before (pre-
dialysis) and after dialysis (post-dialysis). The saliva
was then used to measure the salivary buffering
capacity using the CRT buffer system and salivary
pH was determined using the Merck Universal
indicator system (Merck, Darmstadt, Germany).Clinical follow-up and data collection
During follow-up, patients continued to receive usual
standardized care according to dialysis center protocols
at the entire discretion of the treating clinical team.
Data for total and cause-specific hospitalization and
mortality will be obtained through data linkages to a
centralized database within the Diaverum network. In
this database, every change in patient status in the
clinics is updated by the managing clinician on a
monthly basis, including change of survival status or
from present in clinic or hospitalized, with causes for
death and hospitalization and days of hospital stay.
A cardiovascular-related death or hospitalization in-
cludes death or hospitalization attributed to acute myo-
cardial infarction, pericarditis, atherosclerotic heart
disease, cardiomyopathy, cardiac arrhythmia cardiac ar-
rest, valvular heart disease, pulmonary edema, congestive
cardiac failure, cerebrovascular accident including intra-
cranial hemorrhage, ischemic brain damage including
anoxic encephalopathy, or mesenteric infarction or
ischemia of bowel. An infection-related death includes
septicemia due to internal vascular access, central
nervous system infection (brain abscess, meningitis,
encephalitis), septicemia due to peripheral vascular
disease or gangrene, or other cause, cardiac infection
(endocarditis), pulmonary infection (pneumonia or influ-
enza), abdominal infection (peritonitis, perforated bowel,
diverticular disease, gallbladder), or genito-urinary infec-
tion (urinary tract infection, pyelonephritis, renal
abscess).
Outcomes
The primary outcome for the study is total (all-cause)
mortality associated with different types of oral disease
(such as edentulism, DMFT score, or periodontitis).
Secondary outcomes include death attributable to
cardiovascular causes and death due to infection.
Additional secondary outcomes include total and cause-
specific hospitalization (cardiovascular or infection), and
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DMFT score, periodontitis, oral pain, dysgeusia, precancer-
ous and cancerous lesions, salivary flow rates and saliva
buffering capacity). Prevalence of oral hygiene habits, thirst,
and dysgeusia will also be included in secondary analyses.
Rationale for the number of participants
The sample size for this study is 4700 participants. As-
suming that the prevalence of the exposure (i.e. peri-
odontitis) is about 40% and that 1-year mortality in the
exposed group is 15%, an overall sample of 4700 individ-
uals (2820 with periodontitis and 1880 without) is suffi-
cient to detect a relative reduction of at least 20% in 1-
year mortality (i.e. absolute risk difference of 3%; odds
ratio equal to 0.77) with a power of 80%, where correlation
between exposure and other adjustment covariates = 0.10
and type I error = 0.05.
The large number of participants have also been
recruited so that relatively rare conditions such as
precancerous lesions of the mouth/tongue (estimated
likely prevalence 1% to 3% [21]) can be evaluated. Re-
cruitment has been competitive within the dialysis
network to ensure that at least 4700 valid analyses with
complete datasets and visits are available.
Statistical analysis
Analysis will conform to a predefined statistical analysis
plan agreed between the steering committee and study
statisticians before analysis is commenced. Baseline
sociodemographic and clinical characteristics will be
calculated and expressed as mean (standard deviation)
or median (25th to 75th percentile) for continuous
variables and number (proportion) for categorical vari-
ables. Prevalence and characteristics of oral disease (den-
tal, periodontal, mucosal, and salivary) will be calculated
as number (proportion) affected for categorical variables
and mean (standard deviation) or median (25th to 75th
percentile) for continuous variables. Multivariable logistic
regression models will be built to investigate the influence
of patient demographic and clinical characteristics on risks
of oral disease. We will include as potential variables in
analysis: age, sex, ethnicity, country or residence, educa-
tional status, living situation, occupation status, smoking,
BMI, self-reported appetite, income, financial strain,
comorbidity score, diabetes, existing cardiovascular disease,
depression score, blood pressure, protein catabolic rate,
hemoglobin, albumin, phosphorus, cholesterol, ferritin,
parathyroid hormone, and duration on dialysis.
We will use Cox proportional hazard models for ana-
lysis of mortality and hospitalization outcomes. We will
check for confounders, interactions and multicollinearity
among independent variables. The final models will be
adjusted for all confounders and baseline covariables
judged to have clinical importance. The significance levelwill be set at 0.05. All analyses will be performed using
macro routines written in SAS Language (Release 9.1,
SAS Institute Inc., Cary, NC; 2002–2003; http://www.
sas.com/).
Discussion
Chronic kidney disease is an important and increasing
global public health problem that is associated with
marked loss of quality of life and increased premature
cardiovascular disease and mortality. End-stage kidney
disease, the most severe form of kidney disease, is asso-
ciated with profoundly reduced survival and a heavy
symptom burden, although existing interventions to im-
prove clinical outcomes in this population are generally
lacking. Oral disease may represent an important cause
of impaired quality of life and worse clinical outcomes in
dialysis patients. However, on the basis of current
evidence, data for the characteristics of oral health and
preventative oral hygiene habits in dialysis population
are sparse. Additional large-scale studies of oral health
in this population would assist the prioritization of
future research including appropriate interventional
trials. The ORAL-D study is the first large and compre-
hensive survey of oral disease in adults treated with
long-term hemodialysis. We will evaluate the prevalence,
severity and correlates of oral disease and evaluate the
relationship between oral disease and clinical outcomes
(hospitalization and mortality) in this population.
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